T34228
|
|
|
|
Quinethazone is a thiazide diuretic used to treat hypertension. Common side effects include dizziness, dry mouth, nausea, and low potassium levels. |
T10515
|
|
|
Others
|
Anti-Heart Failure Agent 1 is an orally available compound suitable for the treatment of heart failure without inducing vomiting, nausea, and restlessness. |
T22393
|
|
|
5-HT Receptor
|
Palonosetron, a 5-HT3 antagonist with Ki of 0.17 nM, is used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). |
T71123
|
|
|
|
RG 12915 is a potent, selective 5-HT3 receptor antagonist developed for the treatment of emesis and nausea associated with cancer chemotherapy. |
T15743
|
|
|
Others
|
Methotrimeprazine is an orally available neuroleptic agent. It is commonly used to relieve nausea and vomiting in palliative care settings. Levomepromazine has antagonist actions at multiple neurotransmitter receptor sites, including cholinergic, dopamine |
T38802
|
|
|
|
Trimethobenzamide (Ro 2-9578 free base) is a D2 receptor antagonist and an antiemetic agent. Primarily utilized to mitigate the occurrence of nausea and vomiting, trimethobenzamide effectively blocks the D2 receptor. |
T68371
|
|
|
|
Rolapitant, also known as SCH-619734, is an orally bioavailable, centrally-acting, selective, neurokinin 1 receptor (NK1-receptor) antagonist with potential antiemetic activity. Upon oral administration, rolapitant competitively binds to and blocks the activity of the NK1-receptor in the central nervous system, thereby inhibiting the binding of the endogenous ligand, substance P (SP). This may prevent both SP-induced emesis and chemotherapy-induced nausea and vomiting (CINV). The interaction of SP with the NK1-receptor plays a key role in the induction of nausea and vomiting caused by emetogenic cancer chemotherapy. |
T33583
|
|
S-297995,S297995,Naldemedine,S 297995,S297,995,S 297,995,S297,995;Naldemedine,S-297,995
|
|
Naldemedine (S 297995) is a peripheral selective μ-opioid receptor antagonist being developed by Shionogi for the treatment of opioid-induced adverse reactions, including constipation, nausea, and vomiting. They are usually well tolerated, mainly with mil |
T72820
|
|
|
|
(R)-Casopitant ((R)-GW679769) 是Casopitant 的异构体。Casopitant 是一种 NK(1)-受体拮抗剂。Casopitant 可用于化疗引起的恶心和呕吐的研究。 |
T2589
|
|
|
5-HT Receptor
|
Dolasetron Mesylate hydrate (Dalasetron Mesylate Hydrate) 是一种选择性血清素受体拮抗剂,可竞争性阻断血清素对 5HT3 受体的作用,从而抑制化疗和放疗引起的恶心和呕吐。 |